Loadingβ¦
MARKETS
TOOLS
LEARN
Equiscale Β· Syntellia LLC
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-169M | $-161M | $-139M | -35.2% | - | - |
| 2024 | - | - | - | - | - | - | - |
| 2023 | - | - | - | - | - | - | - |
| 2022 | - | - | - | - | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | - | - | - | 0 |
| Operating Revenue | - | - | - | 0 |
| Operating Expense | - | - | - | 169.08 |
| Research And Development | - | - | - | 138.35 |
| Selling General And Administration | - | - | - | 30.73 |
| Total Expenses | - | - | - | 169.08 |
| Operating Income | - | - | - | -169.08 |
| Total Operating Income As Reported | - | - | - | -169.08 |
| EBITDA | - | - | - | -168.50 |
| Normalized EBITDA | - | -56.73 | - | -168.50 |
| EBIT | - | - | - | -169.08 |
| Interest Income | - | - | - | 5.52 |
| Net Interest Income | - | - | - | 5.52 |
| Other Non Operating Income Expenses | - | -0.51 | - | 2.41 |
| Other Income Expense | - | - | - | 2.41 |
| Interest Income Non Operating | - | - | - | 5.52 |
| Net Non Operating Interest Income Expense | - | - | - | 5.52 |
| Pretax Income | - | - | - | -161.15 |
| Tax Rate For Calcs | - | - | - | 0 |
| Tax Effect Of Unusual Items | - | - | - | 0 |
| Net Income Continuous Operations | - | - | - | -161.15 |
| Net Income From Continuing And Discontinued Operation | - | - | - | -161.15 |
| Net Income From Continuing Operation Net Minority Interest | - | - | - | -161.15 |
| Net Income | - | - | - | -161.15 |
| Net Income Common Stockholders | - | - | - | -161.15 |
| Net Income Including Noncontrolling Interests | - | - | - | -161.15 |
| Normalized Income | - | -55.71 | - | -161.15 |
| Diluted NI Availto Com Stockholders | - | - | - | -161.15 |
| Basic Average Shares | - | - | 26.18 | 8.68 |
| Diluted Average Shares | - | - | 26.18 | 8.68 |
| Reconciled Depreciation | - | - | - | 0.58 |
| General And Administrative Expense | - | - | - | 30.73 |
| Other Gand A | - | - | - | 9.05 |
| Salaries And Wages | - | - | - | 21.69 |
| Earnings From Equity Interest | - | - | - | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MapLight Therapeutics, Inc.this co. | MPLT | $1.4B | - | 2.98 | -35.2% | - |
| AtriCure, Inc. | ATRC | $1.4B | -120.63 | 2.81 | -2.3% | 79.22 |
| Precigen, Inc. | PGEN | $1.4B | -5.49 | 65.81 | -1198.6% | -5.93 |
| Integra LifeSciences Holdings Corporation | IART | $1.4B | -2.65 | 1.31 | -49.5% | -9.72 |
| Butterfly Network, Inc. | BFLY |
| $1.4B |
| - |
| 6.93 |
| -39.3% |
| - |
| UroGen Pharma Ltd. | URGN | $1.3B | -8.76 | -12.75 | 145.5% | -10.04 |
| Bicara Therapeutics Inc. | BCAX | $1.3B | -9.72 | 3.34 | -34.4% | -8.01 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B | -9.56 | 167.49 | -1752.2% | -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B | -21.66 | 7.99 | -36.9% | -50.52 |
| Peer Median | - | -9.56 | 5.13 | -38.1% | -9.72 | |
Historically, Apr has averaged the highest return (+56.8%); Jul the lowest (-63.7%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.7%Neutral MonthJan 2026: +0.71% | -2.4%Negative MonthFeb 2026: -2.37% | +17.7%Positive MonthMar 2026: +17.72% | +56.8%Positive MonthApr 2026: +56.76% | -8.0%Negative MonthMay 2026: -8.03% | +22.3%Positive MonthJun 2026: +22.28% | -63.7%Negative MonthJul 2026: -63.67% | -6.7%*Negative MonthAug 2026: -6.68% | β | β | β | β |
| 2025 | β | β | β | β | β | β | β | β | β | β | -19.4%Negative MonthNov 2025: -19.44% | +28.9%Positive MonthDec 2025: +28.87% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 2 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
